As the National Institute for Health and Care Excellence (NICE) opts not to recommend the gene-specific medicine Orkambi to NHS England, while acknowledging the clinical benefits of the drug, the Cystic Fibrosis Trust has put forward a solution that could speed up access and evaluation.
The Cystic Fibrosis Trust has been working with NHS England and the UK CF Medical Association (UKCFMA) to support the roll out of home monitoring devices and apps to help people with CF stay well at home and spot health problems early during the coronavirus (COVID-19) pandemic.
This week Vertex will meet with NHS England on Wednesday 25 April to discuss further negotiations around access to precision medicine Orkambi and similar future cystic fibrosis (CF) treatments. Lynsey Beswick, Public Affairs Manager at the Cystic Fibrosis Trust, explains what’s happened since last month’s debate in Parliament and what the next steps are for the campaign.
The European Medicines Agency (EMA) has today given marketing authorisation for new cystic fibrosis (CF) medicine Symkevi. This important milestone means that, if an agreement can be reached between the NHS and the manufacturer, Vertex Pharmaceuticals, the treatment could be available for people with CF in the UK.
We’re proud to announce that the Cystic Fibrosis Trust is funding three new Strategic Research Centres that will begin this autumn. This £2.2m investment over three years will involve 20 researchers from five different countries, who will tackle research priorities such as more effective treatments for lung infections and more effective, tailored treatments to improve lung clearance.